Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vyome Holdings, IncOBLN · Entity 1824 | VP Strategic Partnerships | April 30, 2017 | May 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vyome Holdings, Inc
Report date April 30, 2017 · Filed May 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,785 |
Reported balance
After 2017-04-30 transaction · row 1
1 source rowRow 1 · 2017-04-30 · Grant · Acquired 1,785 · Balance 1,785 F1: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2017 Filed May 2, 2017 22:51 UTC | Vyome Holdings, Inc OBLN · Entity 1824 | GrantCommon Stock | 1,785 | $9.03 | $16,118.55 |
DisclosureSEC source: 0001214659-17-002936 · marketforms-38722.xml · nonDerivative · entry 1 Morisey Erin · CIK 0001698303 · VP Strategic Partnerships 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,785 F1 · kind: These shares were acquired under the Obalon Therapeutics, Inc. 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.